Elevated pretreatment serum concentration of YKL-40 - An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer

Cancer

Volumn 116, Issue 17, 2010, Pages 4114-4121

  Thöm, Ina ^a   Andritzky, Birte ^a   Schuch, Gunter ^a   Burkholder, Iris ^b   Edler, Lutz ^b   Johansen, Julia S ^c   Bokemeyer, Carsten ^a   Schumacher, Udo ^a   Laack, Eckart ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarker; Bone lesions; Nonsmall cell lung cancer; YKL 40

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; GEMCITABINE; GLYCOPROTEIN; GLYCOPROTEIN YKL 40; NAVELBINE; UNCLASSIFIED DRUG; ADIPOCYTOKINE; CHI3L1 PROTEIN, HUMAN; LECTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; BLOOD; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; ADIPOKINES;

EID: 77956819725     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25196     Document Type: Article

References (36)

1. Pauk N, Kubik A, Zatloukal P, et al. Lung cancer in women. Lung Cancer. 2005;48:1-9.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
3. Charloux A, Quoix E, Wolkove N, et al. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol. 1997;26:14-23.
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
5. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4:702-709.
6. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4:1604-1614.
7. Bussink AP, Speijer D, Aerts JM, et al. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics. 2007;177:959-970.
8. Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351-360.
9. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221-225.
10. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803-25810.
11. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem. 1995;270:13076-13083.
12. Nordenbaek C, Johansen JS, Junker P, et al. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis. 1999;180:1722-1726.
13. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172-209.
14. Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357:2016-2027.
15. Johansen JS, Jensen BV, Roslind A, et al. Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets. 2007;11:219-234.
16. Junker N, Johansen JS, Andersen CB, et al. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer. 2005;48:223-231.
17. Recklies AD, Ling H, White C, et al. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem. 2005;280:41213-41221.
18. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009;206:1149-1166.
19. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006;12:3935-3941.
20. Nishikawa KC, Millis AJ. GP38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003;287:79-87.
21. Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456-4468.
22. Johansen JS, Lottenburger T, Nielsen HJ, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008;17:2603-2608.
23. Johansen JS, Bojesen SE, Mylin AK, et al. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009;27:572-578.
24. Laack E, Dickgreber N, Muller T, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004;22:2348-2356.
25. Cintin C, Johansen JS, Christensen IJ, et al. Serum YKL-40 and colorectal cancer. Br J Cancer. 1999;79:1494-1499.
26. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9:4423-4434.
27. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004;22:3330-3339.
28. Johansen JS, Drivsholm L, Price PA, et al. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46:333-340.
29. Bergmann OJ, Johansen JS, Klausen TW, et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res. 2005;11:8644-8652.
30. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503-513.
31. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12:5698-5704.
32. Schmidt H, Johansen JS, Gehl J, et al. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139.
33. Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435-442.
34. Mylin AK, Abildgaard N, Johansen JS, et al. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol. 2008;80:310-317.
35. Roslind A, Johansen JS, Christensen IJ, et al. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-863.
36. Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71-77.